Helen Louise Collins - 17 Aug 2026 Form 4 Insider Report for Enliven Therapeutics, Inc. (ELVN)

Reporting relationship: CHIEF MEDICAL OFFICER
Issuer ticker: ELVN
Reported as of: 17 Aug 2026
Net transaction value: -$292,931
SEC form: 4
Accepted by SEC: 19 Aug 2026, 16:16:13 UTC
Prior SEC filing: 21 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Ben Hohl, by power of attorney

Key filing fact

Helen Louise Collins filed Form 4 for Enliven Therapeutics, Inc. (ELVN) on 19 Aug 2026.

Key facts

This page summarizes Helen Louise Collins's Form 4 filing for Enliven Therapeutics, Inc. (ELVN).
4 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 19 Aug 2026, 16:16.

Change

Previous filing in this sequence was filed on 21 Jul 2026.
Current net transaction value: -$292,931.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001701247 Primary reporting owner

Collins Helen Louise

Relationship: CHIEF MEDICAL OFFICER
Address: C/O ENLIVEN THERAPEUTICS, INC., 205 PARK ROAD, BURLINGAME
Signature: /s/ Ben Hohl, by power of attorney
Signature date: 19 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ELVN transaction

Common Stock

Options Exercise

Transaction value
Shares: +5,000
Change %: +20%
Price: $2.48^*
Shares after: 30,000
Date: 17 Aug 2026
Ownership: Direct
Footnotes: F1, F2

ELVN transaction

Common Stock

Sale

Transaction value: $227,650
Shares: -3,900
Change %: -13%
Price: $58.37
Shares after: 26,100
Date: 17 Aug 2026
Ownership: Direct
Footnotes: F1, F2, F3

ELVN transaction

Common Stock

Sale

Transaction value: $65,281
Shares: -1,100
Change %: -4.2%
Price: $59.35
Shares after: 25,000
Date: 17 Aug 2026
Ownership: Direct
Footnotes: F1, F4, F5

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ELVN transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value
Shares: -5,000
Change %: -4.3%
Price: $0.000000^*
Shares after: 111,268
Date: 17 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,000
Exercise price: $2.48
Footnotes: F1, F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 6 footnotes

Footnote F1

The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025.

Footnote F2

Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

Footnote F3

This transaction was executed in multiple trades at prices ranging from $57.895 to $58.84. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Footnote F4

This transaction was executed in multiple trades at prices ranging from $58.985 to $59.535. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Footnote F5

These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

Footnote F6

All of the shares subject to this option are fully vested and exercisable as of the date hereof.